Aggrenox HCP Home

Stroke and TIA Facts

Up to 30% of stroke survivors are disabled — it is a leading cause of long-term adult disability in the U.S.¹
The most common vascular event in the first few years after transient ischemic attack (TIA)/stroke is a recurrent stroke.²
50% of all stroke/TIA patients will have a repeat event within one year.¹
Unlike a stroke, a TIA usually lasts only a few minutes and there is no permanent damage to the brain.

Common Signs and Symptoms⁴

Brief period of weakness or numbness of the face, arm, or leg, especially on one side of the body
Brief period of confusion or trouble speaking or understanding
Trouble seeing in one or both eyes for a brief period of time
Trouble walking, dizziness, or loss of balance or coordination for a brief period of time
Brief period of severe headache with no known cause

Urgency to Treat

Nearly 1 in 5 TIA/stroke patients is at risk of a repeat event within 3 months.³
Risk of recurrent TIA/stroke within 6 months after a TIA is 26%.⁶
About 8% of strokes that occur after a TIA strike within 7 days.³
Up to 25% of patients will die within a year of a TIA.¹

Need for Patient Education

Because of its short duration and lack of permanent effects, a TIA is easy for a patient to dismiss or forget.

Download these materials to further support your efforts to educate your patients on TIA signs and symptoms and help them better understand the relationship between TIA and recurrent stroke.

TIA Factsheet

TIA Patient Brochure

National Stroke Association: Aspirin (50 mg) plus extended-release dipyridamole (200 mg twice daily) [AGGRENOX] is a first-choice option to reduce the risk of stroke following a noncardioembolic TIA. (Category 1)⁷
American Heart Association: On the basis of comparative clinical studies, the combination of aspirin and extended-release dipyridamole is recommended over aspirin alone. (Class IIa, Level of Evidence A)⁸

Read more at my.americanheart.org.
American College of Chest...: In patients with known noncardioembolic stroke or TIA, the combination of aspirin and extended-release dipyridamole (25 mg/200 mg BID) is recommended over aspirin (Grade 2A)⁹

AGGRENOX prevents twice as many recurrent strokes as aspirin…¹⁰ Journal of the Neurological Sciences 1996;143:1-13 Details
AGGRENOX is especially effective for high risk patients…¹¹ Arch Neurol. 2005;62:403-408 Details
AGGRENOX has been proven safe and effective for all recurrent stroke patients…¹⁰ Journal of the Neurological Sciences 1996;143:1-13 Details

If your patients can't afford AGGRENOX, our patient assistance program may be able to help. Call 1 800 556 8317.

Important Information About AGGRENOX

AGGRENOX is indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis.

In clinical trials, the most common adverse event with AGGRENOX was headache (38.2% vs 32.4% with placebo), which was more frequent at the onset of therapy but diminished over time.¹⁰ GI bleeding with AGGRENOX was comparable to aspirin (4.1% vs 3.2%) and intracranial hemorrhage with AGGRENOX was similar to placebo (0.6% vs 0.4%).

AGGRENOX contains aspirin. Patients who consume three or more alcoholic drinks every day should be counseled about the bleeding risks involved with chronic, heavy alcohol use while taking aspirin. Even low doses of aspirin can increase bleeding time, which can adversely affect patients with bleeding disorders. Patients with a history of active peptic ulcer disease should avoid using aspirin, which can cause gastric mucosal irritation and bleeding. AGGRENOX should be avoided in the third trimester of pregnancy.

Click here for full AGGRENOX Prescribing Information.